Jang Yeong-Su, Sim Jae Jun, Ji Eunhee, Jeong Keun-Yeong, Kim Hwan Mook
Gachon Institute of Pharmaceutical Science, Gachon University, Incheon, Republic of Korea.
Gachon Institute of Pharmaceutical Science, Gachon University, Incheon, Republic of Korea.
Life Sci. 2015 Oct 15;139:160-5. doi: 10.1016/j.lfs.2015.08.012. Epub 2015 Aug 24.
Calcium supplements appear to reduce the risk of developing colorectal cancer (CRC), and it is necessary to clarify the mechanisms by which they exert their effects. In the present study, we investigate the supplementation effect of calcium via lactate calcium salt (CaLa) on CRC cells, focusing on β-catenin destabilization.
The clonogenic assay was performed using different doses of CaLa. The expression level of c-Myc and Cyclin D1 was measured in addition to the confirmation of β-catenin expression in the CRC cells. Glycogen synthase kinase (GSK)-3β expression was also confirmed in order to investigate the mechanism of β-catenin degradation. Tumorigenic ability was confirmed using a xenograft animal model.
The number of colonies was significantly decreased after 2.5mM CaLa treatment. CaLa-treated CRC cells showed a decrease in the β-catenin expression. The quantitative level of the β-catenin protein was significantly decreased in the CRC cell lysates, hence the expression level of c-Myc and cyclin D1 was significantly decreased following 2.5mM CaLa treatment. We also confirmed that an increased expression of GSK-3β by CaLa is a key pathway in β-catenin degradation. In the xenograft study, tumorigenicity was significantly inhibited to a maximum of 45% in the CaLa-treated group as compared with the control.
These results support the idea that calcium supplementation via CaLa contributes to β-catenin degradation and is hypothesized to reduce the risk of CRC. In addition, it indicates the possibility of CaLa being a potential incorporating agent with existing therapeutics against CRC.
钙补充剂似乎可降低患结直肠癌(CRC)的风险,有必要阐明其发挥作用的机制。在本研究中,我们研究了乳酸钙盐(CaLa)形式的钙对CRC细胞的补充作用,重点关注β-连环蛋白的失稳。
使用不同剂量的CaLa进行克隆形成试验。除了确认CRC细胞中β-连环蛋白的表达外,还测量了c-Myc和细胞周期蛋白D1的表达水平。为了研究β-连环蛋白降解的机制,还确认了糖原合酶激酶(GSK)-3β的表达。使用异种移植动物模型确认致瘤能力。
2.5mM CaLa处理后,菌落数量显著减少。CaLa处理的CRC细胞中β-连环蛋白表达降低。CRC细胞裂解物中β-连环蛋白蛋白的定量水平显著降低,因此2.5mM CaLa处理后c-Myc和细胞周期蛋白D1的表达水平显著降低。我们还证实,CaLa使GSK-3β表达增加是β-连环蛋白降解中的关键途径。在异种移植研究中,与对照组相比,CaLa处理组的致瘤性显著受到抑制,最高可达45%。
这些结果支持通过CaLa补充钙有助于β-连环蛋白降解的观点,并推测可降低患CRC的风险。此外,这表明CaLa有可能成为现有CRC治疗药物的潜在联合用药。